Keyphrases
Peripheral T-cell Lymphoma
98%
T-cell Lymphoma
82%
Relapsed or Refractory
68%
Brentuximab Vedotin
45%
Lymphoma
44%
Diffuse Large B-cell Lymphoma (DLBCL)
38%
Cutaneous T-cell Lymphoma
34%
Rituximab
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
30%
Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
29%
Mycosis Fungoides
27%
Romidepsin
25%
Anaplastic Large Cell Lymphoma
24%
Lenalidomide
24%
Initial Treatment
19%
Phase II Study
19%
NCCN Guidelines
19%
Transplant Eligibility
19%
Non-Hodgkin Lymphoma
18%
Progression-free Survival
18%
Angioimmunoblastic T-cell Lymphoma
17%
Histone Deacetylase Inhibitor (HDACi)
16%
Hepatosplenic T-cell Lymphoma
16%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
T Cells
15%
Nivolumab
14%
Adult T-cell Leukemia
13%
R-CHOP
13%
Whole Exome Sequencing
13%
Overall Survival
13%
Mantle Cell Lymphoma
12%
Phase I Study
12%
T-follicular Helper Phenotype
12%
Risk Stratification
12%
Cytarabine
12%
Duvelisib
12%
Partial Response
12%
Follicular Lymphoma
11%
Previously Untreated
11%
Breast
11%
Primary Mediastinal Large B-cell Lymphoma
11%
Classical Hodgkin Lymphoma
11%
Bendamustine-rituximab
11%
Whole Genome Sequencing
11%
Improved Outcomes
11%
Quality of Life
11%
Response Rate
11%
Lymphoma Patients
10%
Aggressive Lymphoma
10%
Confidence Interval
10%
Medicine and Dentistry
Peripheral T-Cell Lymphoma
100%
T-Cell Lymphoma
79%
Anaplastic Large Cell Lymphoma
45%
Transplantation
38%
Brentuximab Vedotin
35%
Non-Hodgkin Lymphoma
34%
Diseases
33%
Neoplasm
32%
Breast Implant
29%
T Cell
28%
Cutaneous T Cell Lymphoma
28%
Diffuse Large B-Cell Lymphoma
26%
Lenalidomide
23%
Mycosis fungoides
23%
Overall Survival
22%
Quality of Life
20%
Romidepsin
19%
Rituximab
19%
Progression Free Survival
18%
Natural Killer Cell
18%
Large-Cell Lymphoma
17%
Angioimmunoblastic T-Cell Lymphoma
17%
CHOP
16%
Malignant Neoplasm
16%
Stem Cell Transplant
16%
Positron Emission Tomography-Computed Tomography
15%
Nivolumab
14%
Adult T-Cell Leukemia/Lymphoma
14%
Mantle Cell Lymphoma
12%
Cytarabine
12%
Histone Deacetylase Inhibitor
12%
Biological Marker
12%
Bendamustine
11%
Classical Hodgkin Lymphoma
11%
Central Nervous System
11%
Arm
11%
NK T Cell Lymphoma
11%
Adverse Event
11%
Hepatosplenic T-Cell Lymphoma
10%
Cutaneous Lymphoma
10%
B Cell
9%
Oncology
9%
Exome Sequencing
8%
Lupus Erythematosus Panniculitis
8%
Gemcitabine
8%
Targeted Therapy
8%
Aggressive Lymphoma
8%
Hematopoietic Cell
8%
Anaplastic Lymphoma Kinase
7%
Clinical Decision Making
7%